Video wird geladen...

Video konnte nicht geladen werden

Zur Startseite

Introducing Latent-X2 — AI-generated antibodies with drug-like developability and low immunogenicity in human panels, zero-shot. Technical report: Blog: Apply for access: [email protected]

54,814 Aufrufe • vor 9 Monaten •via X (Twitter)

29 Kommentare

Profilbild von Jeff Dean
Jeff Deanvor 9 Monaten

Congrats! 🎉

Profilbild von Simon Kohl
Simon Kohlvor 9 Monaten

Thank you, Jeff!!!

Profilbild von Simon Kohl
Simon Kohlvor 9 Monaten

Latent-X2 achieves high-affinity binders across modalities: scFv fragments — down to low picomolar VHH nanobodies — nanomolar affinities Macrocyclic peptides — hits on K-Ras, matching trillion-scale screens Testing just 4-24 designs per experiment. And as part of our report, we release lab-confirmed binder sequences for each of them.

Profilbild von Simon Kohl
Simon Kohlvor 9 Monaten

But the real breakthrough isn't binding, it's developability. Our designs match or exceed approved therapeutics in head-to-head comparison. Expression yield, thermostability, polyreactivity — drug-like from the first generation.

Profilbild von Simon Kohl
Simon Kohlvor 9 Monaten

And for the first time: immunogenicity assessment of an AI-generated antibody. Latent-X2 VHH binders cleared ex vivo T-cell activation and cytokine release assays across a ten-donor human panel. A critical milestone for clinical translation.

Profilbild von Simon Kohl
Simon Kohlvor 9 Monaten

To enable reproduction, we're publishing the sequence and structure of a lab-validated antibody design for each target — accessible on the Latent Labs Platform without sign-in. See the lab-validated examples section on:

Profilbild von Simon Kohl
Simon Kohlvor 9 Monaten

Super excited to also welcome Stefan Oschmann, former CEO of Merck KGaA, to our strategic advisory board. Drug discovery has long been bottlenecked not by hits, but by development. With Latent-X2, we're getting closer to designing the right molecule from the start.

Profilbild von Simon Kohl
Simon Kohlvor 9 Monaten

Just five months after Latent-X1. Grateful to the team for pushing the frontier. Latent-X2 is available on the Latent Labs Platform, via API and in partnerships with us. Reach out: [email protected] More to come. 🚀

Profilbild von Simon Kohl
Simon Kohlvor 9 Monaten

Check out the antibody design workflow on our platform. I am proud of how easy to use this frontier technology can feel.

Profilbild von Robin Rombach
Robin Rombachvor 9 Monaten

🔥 congrats, Simon!

Profilbild von Simon Kohl
Simon Kohlvor 9 Monaten

Thank you @robrombach - and ofc amazing to have you contribute!

Profilbild von Rishabh
Rishabhvor 9 Monaten

Congrats to the team!! Looks awesome :D

Profilbild von Simon Kohl
Simon Kohlvor 9 Monaten

Thank you, Rishabh!

Profilbild von Chaitanya K. Joshi
Chaitanya K. Joshivor 9 Monaten

Congrats team!

Profilbild von Simon Kohl
Simon Kohlvor 9 Monaten

Thank you Chaitanya!

Profilbild von Karsten Kreis
Karsten Kreisvor 9 Monaten

Congrats to you and the team, Simon! 🔥

Profilbild von Simon Kohl
Simon Kohlvor 9 Monaten

Thanks a lot Karsten!

Profilbild von Anthara Fairooz
Anthara Fairoozvor 9 Monaten

Exciting innovation! Looking forward to seeing the impact of Latent-X2.

Profilbild von Rishabh Poddar
Rishabh Poddarvor 9 Monaten

I wish more people did work like this!

Profilbild von Rahul
Rahulvor 9 Monaten

Congratulations @saakohl! Latent-X is a game-changer for computational biology and drug discovery, pushing button for picomolar binders could slash timelines on undruggable targets like never before. AI in Science exploding! 🔥

Profilbild von nabajit (bio/acc)
nabajit (bio/acc)vor 9 Monaten

very cool

Profilbild von MrHonkster
MrHonkstervor 9 Monaten

Saving to read later

Profilbild von Amy - AI Girl
Amy - AI Girlvor 9 Monaten

Exciting advancement in AI-generated antibodies! Great potential for health innovation.

Profilbild von Arda Göreci
Arda Görecivor 9 Monaten

Congrats Simon!

Profilbild von PurePckg
PurePckgvor 9 Monaten

May I ask who was responsible for the frontend development using Mol*? The glass‑like rendering and the elegant handling of selections in each component are truly impressive.

Profilbild von Ava Grace
Ava Gracevor 9 Monaten

Exciting innovation in AI-generated antibodies!

Profilbild von Tony Kulesa
Tony Kulesavor 9 Monaten

🔥

Profilbild von Evgenii
Evgeniivor 9 Monaten

Nice affinities. It's a pity that no proofs are presented.

Profilbild von Sam Dare
Sam Darevor 9 Monaten

@micaelabazo @metanova_labs wen?

Ähnliche Videos

Today, we expand zero-shot drug design beyond binding to the design of multifunctional medicines, the intracellular proteome, and state-of-the-art atomic precision with our model, JAM-2. In a new report (below), we show: 1. The first drug-grade, fully computationally designed multispecific antibodies against five peptide-MHCs: Routine picomolar T-cell activation/cell-killing EC50s, >100-fold selectivity, and drug-like developability 2. The first fully generatively designed, drug-grade dual-variant KRAS G12 multispecifics: They recruit primary T-cells from human donors to kill G12V and G12C presenting cells at pM to single-digit-nM potency, completely sparing wild-type. 3. Atomic accuracy, from sequence alone: Angstrom-level agreement between Cryo-EM and JAM-2 de novo designs, requiring only target sequences (not structure) as input. 4. Unrivaled speed with an AI-native in-house wet lab: Designed, built, and tested five programs in one parallelized campaign, end-to-end in-house in ~6 weeks. 5. A higher validation bar for AI-generated drug candidates: In a field increasingly rife with hype and uneven standards of proof, we provide the highest quality public wet-lab validation of AI-designed antibodies to date. We share experimental methods in full, and invite folks to adopt and build on these standards. Truly individualized therapies will be the most important contribution of AI in drug design. These advances help accelerate this future.

Nabla Bio

180,591 Aufrufe • vor 3 Monaten